Poster Session E - Tuesday Afternoon
Category: IBD
David M. Faleck, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Patient | Age of ICI Initiation & IBD type | IBD Duration (years) & Prior IBD Medications | Lynch Syndrome | Cancer Stage | ICI Type & Doses of ICI | Treatment for IBD Flare | Best overall Cancer Response to ICI | Surgery for CRC |
1 | 51, Crohn's | 38; SSZ, CS, IFX | No | IV | PD- 1, 33 | Prednisone, Adalimumab, Ustekinumab | Partial Response | Subtotal colectomy (before ICI) |
2 | 50, Crohn's | 23; 6-MP | No | IV | PD- 1, 10 | N/A | Partial Response | Total proctocolectomy with end ileostomy (before ICI) |
3 | 35, UC | 22; 5-ASA | Yes | III | PD- 1, 33 | 5-ASA | Complete Response | None |
4 | 34, UC | 22; 5-ASA, CS,AZA | Yes | III | PD- 1, 4 | 5-ASA | Partial Response | Total proctocolectomy with ileoanal anastomosis (after ICI) |
ADA: adalimumab, AZA: azathioprine; CRC- Colorectal Cancer; CS: corticosteroids; CTCAE: Common Terminology Criteria for Adverse Events, IBD: inflammatory bowel disease, ICI: immune checkpoint inhibitor; IFX: infliximab; PD-1: Programmed Death 1; SSZ: sulfasalazine; 5-ASA: 5-aminosalicylate; 6- MP : 6-mercaptopurine; UC: ulcerative colitis